BioSpace News Archive

Ventus Therapeutics announced that it has been named a “Fierce 15” company in Fierce Biotech’s 2023 annual report featuring the most innovative and promising biotechnology companies in the industry.

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) today announced that it will be presenting analyses highlighting patient-focused endpoints from its Essential1 study of ulixacaltamide (PRAX-944) in essential tremor (ET) at The International Parkinson and Movement Disorder Society’s (MDS) International Congress of Parkinson’s Disease and Movement Disorders®, taking place in Copenhagen, Denmark.

Genelux Corporation, a late clinical-stage immuno-oncology company, announced that Lourie S. Zak will join the company as Chief Financial Officer, effective August 28, 2023.

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that all samples and data required for a readout of topline results from the Phase 2b SYMMETRY study have been collected, which supports the expected timing of readout in October of this year.

Allucent announced that it has been selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services to accelerate clinical research and development for next-generation COVID-19 vaccine candidates.

Comanche Biopharma Corp. is pleased to announce that Fierce Biotech has named it as one of its 2023 “Fierce 15", designating Comanche as one of the most promising early-stage biotechnology companies in the industry.

Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company has entered into a discovery and development collaboration with GenFleet Therapeutics (“GenFleet”) to advance three oncology discovery programs targeting RAS pathway-driven cancers.

AlloVir, Inc. announced that Diana Brainard, M.D., Chief Executive Officer, will participate in the following upcoming investor conferences: Morgan Stanley 21st Annual Global Healthcare Conference Fireside Chat: Monday, September 11, 2023 at 4:55 pm ET H.C.

Soterix Medical Inc. announces the launch of a Phase-2 clinical trial that will evaluate the combination of REMOTE-tDCS and a brain training program for the treatment of long COVID.

Invitae, a leading medical genetics company, announced that it has appointed Robert Guigley as its chief commercial officer, effective September 5, 2023.